Xifaxan

PreclinicalSmall molecule

MMayo Clinic

Xifaxan is one of 63 small molecule programs targeting Abdominal pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal PainActive, not recruiting

GrowthActive, not recruiting

Abdominal PainPreclinical

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

79 competitors in Growth

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

30 2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 3

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

8 4

Piqray

Novartis

Phase 2

2 5

Acipimox

Boehringer Ingelheim

Phase 2

1 6

Zyloprim

Jazz Pharmaceuticals

Preclinical

1 7

Lenvima

Eisai

Preclinical

1 8

Zolymbus

AbbVie

Preclinical

1 9

Aricept

Eisai

Preclinical

1 10

TY-9591

TTYK Medicines, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

Terminated·MMayo Clinic·N/A·NCT00577772·17 enrolled

Abdominal pain1 trial

Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?

Completed·—·N/A·NCT00619970·115 enrolled

Liver Resection1 trial

Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

Terminated·RRWTH Aachen University·Phase 2·NCT02555293·96 enrolled

Pilot Study1 trial

A Pilot Study of Xifaxan to Treat Patients With PSC

Completed·MMayo Clinic·Phase 1·NCT01695174·16 enrolled

Diarrhea1 trial

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Completed·AActavis Inc.·Phase 3·NCT02498418·739 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Xifaxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xifaxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xifaxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

Xifaxan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Abdominal pain1 trial

Liver Resection1 trial

Pilot Study1 trial

Diarrhea1 trial

References

Drug Info

Quick Facts

Related News